Harpinder K Brar, Jiney Jose, Zimei Wu, Manisha Sharma
6 min
Glioblastoma multiforme (GBM) is a highly aggressive, grade IV brain tumor characterized by rapid invasion, significant genetic heterogeneity, and poor patient prognosis. Despite standard treatments—surgical resection, radiotherapy, and chemotherapy with temozolomide—recurrence is almost inevitable. The infiltrative nature of the tumor makes complete surgical removal impossible, and the blood-brain barrier (BBB) prevents many therapeutic agents from reaching the tumor site at effective concentrations.
Tyrosine kinases (TKs) are essential regulators of cell signaling pathways, including those governing proliferation, angiogenesis, and survival. Abnormalities in receptor tyrosine kinase (RTK) signaling are implicated in over 80% of GBM cases. While tyrosine kinase inhibitors (TKIs) have revolutionized treatment for other cancers, they have largely failed in GBM clinical trials. The primary reasons for this failure are the inability of these drugs to cross the BBB in sufficient quantities and a lack of tumor-specific targeting, which limits their therapeutic window.
To overcome the limitations of TKIs, researchers are shifting focus toward advanced drug delivery systems. Nanocarriers are particularly promising because they can be engineered to bypass or cross the BBB, protect the drug from premature degradation in the bloodstream, and facilitate either passive or active targeting of tumor cells. Furthermore, nanocarrier systems allow for controlled drug release and support non-invasive delivery routes, such as intranasal administration, which can provide a direct pathway to the brain, bypassing the systemic circulation and the BBB entirely.
Glioblastoma multiforme (GBM) is an aggressive brain tumor with high mortality rates. Due to its invasiveness, heterogeneity, and incomplete resection, the treatment is very challenging. Targeted therapies such as tyrosine kinase inhibitors (TKIs) have great potential for GBM treatment, however, their efficacy is primarily limited by poor brain distribution due to the presence of the blood-brain barrier (BBB). This review focuses on the potential of TKIs in GBM therapy and provides an insight into the reasons behind unsuccessful clinical trials of TKIs in GBM despite the success in treating other cancer types. The main section is dedicated to the use of promising drug delivery strategies for targeted delivery to brain tumors. Use of brain targeted delivery strategies can help enhance the efficacy of TKIs in GBM. Among various drug delivery approaches used to bypass or cross BBB, utilizing nanocarriers is a promising strategy to augment the pharmacokinetic properties of TKIs and overcome their limitations. This is because of their advantages such as the ability to cross BBB, chemical stabilization of drug in circulation, passive or active targeting of tumor, modulation of drug release from the carrier, and the possibility to be delivered via non-invasive intranasal route.
Sam: And without the brakes, the cells just keep multiplying?
Alex: Continuously. And because these genes are gone, the cells become far more sensitive to growth signals — they're essentially flooring the accelerator at the same time the brakes are cut. The paper notes this is common in primary glioblastoma tumors, which makes them both aggressive and difficult to slow down.
Sam: So there's a double problem: the drug can't get in, and even if it did, the tumor is built to ignore the body's own stop signals.
Alex: Exactly. And on top of that, these tumors hijack the body's inflammatory signals — molecules called interleukins — to build their own blood supply and help the tumor spread further into surrounding tissue. The tumor isn't just growing; it's actively constructing infrastructure to support that growth.
Sam: It's almost like it's setting up its own city inside the brain.
Alex: That's a fair way to put it. Which is why the paper emphasizes that understanding this internal environment matters just as much as solving the delivery problem. Without an accurate picture of how the tumor operates, any treatment strategy is working with incomplete information.
Sam: And even when researchers do find a way to open the blood-brain barrier — say, with ultrasound — the tumor has yet another defense waiting inside?
Alex: That's right. The paper describes what are called efflux transporters. Think of them as tiny automated bouncers stationed inside the cell. Their job is to scan for foreign substances — including medicine — and physically eject them back out into the bloodstream before they can do any damage to the tumor.
Sam: So a drug could slip past the fortress wall, and then immediately get thrown out by the bouncers inside?
Alex: Precisely. This is one of the key reasons chemotherapy so often falls short. The cells are pumping the medicine out as fast as it arrives, keeping the concentration inside the tumor far too low to be effective. Opening the barrier with ultrasound helps, but if the bouncers are still active, the drug still gets ejected.
Sam: So you have to solve both problems simultaneously — get through the gate and neutralize the bouncers.
Alex: That is the core of what the paper is arguing. Researchers are testing compounds that act like jammers — molecules that block the ejection mechanism and keep the medicine inside the cell long enough to work. The paper specifically notes that a drug called erlotinib is a frequent target for these transporters. When scientists blocked the transporters, erlotinib was finally able to stay inside the tumor cells at a useful concentration.
Sam: It really is a layered problem. Physical barrier, cellular machinery, broken internal brakes, hijacked inflammation signals. Each layer has to be addressed.
Alex: And that's precisely why the paper frames this as a systems challenge rather than a single-drug problem. The research suggests that a successful treatment strategy for glioblastoma will likely need to combine smarter delivery — whether through nanocarriers, intranasal routes, or barrier-opening techniques — with methods that disable the tumor's internal defenses. No single piece solves it alone.
Sam: It reframes the whole question. It's less "why doesn't this drug work?" and more "how do we build a complete system that gives the drug a fighting chance?"
Alex: That's a precise way to put it. And it's a question this paper takes seriously — not by offering a final answer, but by mapping the obstacles clearly enough that future research has somewhere meaningful to start. Thanks for listening to ResearchPod.